title: Gd(ABE-DTTA), a novel contrast agent, at the MRI-effective dose shows absence of deleterious physiological effects in dogs.
abstract: The physiological effects of a novel MRI contrast agent, Gd(ABE-DTTA), were investigated in dogs, monitoring parameters in blood samples. Each animal (n = 8 in the short-term, n = 4 in the long-term group) underwent isoflurane anesthesia followed by the generation of myocardial infarction and received a contrast agent at the MRI effective dose. Blood samples were collected 24 and 48 h, and 7, 14, 28, 35, 49 and 56 days after contrast agent administration. No significant changes exceeding the normal range were detected in any of the investigated parameters except in alanine aminotransferase (ALT). ALT enzyme activity increased in the short-term group 24 and 48 h after agent administration as expected from the effect of isoflurane anesthesia. Between days 7 and 56 no elevation in ALT was observed. In dogs no substantial short- or long-term effect was observed on the investigated, physiological parameters after Gd(ABE-DTTA) administration at the MRI effective dose.
authors.affiliation: Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294-0005, USA.
authors.forename: Balázs
authors.initials: B
authors.lastname: Ruzsics
authors.forename: Pál
authors.initials: P
authors.lastname: Surányi
authors.forename: Pál
authors.initials: P
authors.lastname: Kiss
authors.forename: Brigitta C
authors.initials: BC
authors.lastname: Brott
authors.forename: Ada
authors.initials: A
authors.lastname: Elgavish
authors.forename: Nada H
authors.initials: NH
authors.lastname: Saab-Ismail
authors.forename: Tamás
authors.initials: T
authors.lastname: Simor
authors.forename: Gabriel A
authors.initials: GA
authors.lastname: Elgavish
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000681:Amylases / Q000097:blood / Q000378:metabolism; D018685:Anesthetics, Inhalation / Q000008:administration & dosage; D000818:Animals; D001798:Blood Proteins / Q000032:analysis / Q000378:metabolism; D003287:Contrast Media / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D004285:Dogs; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004573:Electrolytes / Q000097:blood; D004906:Erythrocyte Count; D007530:Isoflurane / Q000008:administration & dosage; D007677:Kidney Function Tests / Q000379:methods; D007958:Leukocyte Count; D008111:Liver Function Tests / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D015394:Molecular Structure; D017202:Myocardial Ischemia / Q000139:chemically induced / Q000175:diagnosis; D009942:Organometallic Compounds / Q000097:blood / Q000737:chemistry / Q000494:pharmacology*; D004369:Pentetic Acid / Q000097:blood / Q000737:chemistry / Q000494:pharmacology; D013997:Time Factors
chemical_list: D018685:Anesthetics, Inhalation; D001798:Blood Proteins; D003287:Contrast Media; D004573:Electrolytes; D009942:Organometallic Compounds; C120791:gadolinium N-(2-butyryloxyethyl)-N'-(2-ethyloxyethyl)-N,N'-bis(N'',N''-bis(carboxymethyl)acetamido)-1,2-ethanediamine; D004369:Pentetic Acid; D007530:Isoflurane; D000410:Alanine Transaminase; D000681:Amylases